Our progress against sarcoma
Paediatric and young adult sarcomas
Our researchers led the discovery that cediranib, a drug that blocks blood vessel growth, can be an effective treatment for alveolar soft part sarcoma, a particularly rare cancer with limited treatment options.
ICR scientists were also involved in a global study that shed light on the mutations that increase the chances of sarcoma and other cancers, such as breast cancer, across families, helping to establish genetic counselling and screening for those at risk.
Researchers at the ICR and Breast Cancer Now Toby Robins Research Centre found that synovial sarcoma – which develops around joints and tendons, and mostly affects young people – can be treated with drugs that stop DNA damage repair.
Support the vital work of our researchers in discovering new, kinder treatments for sarcoma in children and young adults.
Centres and collaborations
Our upcoming Sarcoma Accelerator Consortium, led by Professor Robin Jones, will be the world’s largest digital hub of clinical and research data on sarcomas, incorporating artificial intelligence to predict and test how sarcoma patients respond to drugs.
The consortium aims to improve outcomes for patients by identifying new drug targets, developing disease models and creating digital tools to help with prognosis.
Our Joint Sarcoma Research Centre – a virtual collaboration with The Royal Marsden – brings together sarcoma researchers and clinicians to develop new treatments and therapies, including those tailored to individual patients.